Trading in shares of dual-listed healthcare product company Ebos will resume this morning after the company said that a rumoured multi-billion dollar acquisition will not proceed.
Last Thursday, Ebos went into a trading halt after the Australian Financial Review reported it was eyeing up a deal for
Want to read more? It's easy.
Choose your best value subscription option
Student
Exclusive offer for uni students studying at a New Zealand university (valued at $499).
